294 related articles for article (PubMed ID: 22479189)
1. LMW-E/CDK2 deregulates acinar morphogenesis, induces tumorigenesis, and associates with the activated b-Raf-ERK1/2-mTOR pathway in breast cancer patients.
Duong MT; Akli S; Wei C; Wingate HF; Liu W; Lu Y; Yi M; Mills GB; Hunt KK; Keyomarsi K
PLoS Genet; 2012; 8(3):e1002538. PubMed ID: 22479189
[TBL] [Abstract][Full Text] [Related]
2. Cdk2 is required for breast cancer mediated by the low-molecular-weight isoform of cyclin E.
Akli S; Van Pelt CS; Bui T; Meijer L; Keyomarsi K
Cancer Res; 2011 May; 71(9):3377-86. PubMed ID: 21385896
[TBL] [Abstract][Full Text] [Related]
3. Targeting low molecular weight cyclin E (LMW-E) in breast cancer.
Nanos-Webb A; Jabbour NA; Multani AS; Wingate H; Oumata N; Galons H; Joseph B; Meijer L; Hunt KK; Keyomarsi K
Breast Cancer Res Treat; 2012 Apr; 132(2):575-88. PubMed ID: 21695458
[TBL] [Abstract][Full Text] [Related]
4. Low-molecular-weight cyclin E can bypass letrozole-induced G1 arrest in human breast cancer cells and tumors.
Akli S; Bui T; Wingate H; Biernacka A; Moulder S; Tucker SL; Hunt KK; Keyomarsi K
Clin Cancer Res; 2010 Feb; 16(4):1179-90. PubMed ID: 20145171
[TBL] [Abstract][Full Text] [Related]
5. Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells.
Ambrosini G; Cheema HS; Seelman S; Teed A; Sambol EB; Singer S; Schwartz GK
Mol Cancer Ther; 2008 Apr; 7(4):890-6. PubMed ID: 18413802
[TBL] [Abstract][Full Text] [Related]
6. Low-Molecular-Weight Cyclin E in Human Cancer: Cellular Consequences and Opportunities for Targeted Therapies.
Caruso JA; Duong MT; Carey JPW; Hunt KK; Keyomarsi K
Cancer Res; 2018 Oct; 78(19):5481-5491. PubMed ID: 30194068
[TBL] [Abstract][Full Text] [Related]
7. Cytoplasmic Cyclin E Mediates Resistance to Aromatase Inhibitors in Breast Cancer.
Doostan I; Karakas C; Kohansal M; Low KH; Ellis MJ; Olson JA; Suman VJ; Hunt KK; Moulder SL; Keyomarsi K
Clin Cancer Res; 2017 Dec; 23(23):7288-7300. PubMed ID: 28947566
[No Abstract] [Full Text] [Related]
8. Cyclic AMP/PKA-dependent paradoxical activation of Raf/MEK/ERK signaling in polycystin-2 defective mice treated with sorafenib.
Spirli C; Morell CM; Locatelli L; Okolicsanyi S; Ferrero C; Kim AK; Fabris L; Fiorotto R; Strazzabosco M
Hepatology; 2012 Dec; 56(6):2363-74. PubMed ID: 22653837
[TBL] [Abstract][Full Text] [Related]
9. Overexpression of the low molecular weight cyclin E in transgenic mice induces metastatic mammary carcinomas through the disruption of the ARF-p53 pathway.
Akli S; Van Pelt CS; Bui T; Multani AS; Chang S; Johnson D; Tucker S; Keyomarsi K
Cancer Res; 2007 Aug; 67(15):7212-22. PubMed ID: 17671189
[TBL] [Abstract][Full Text] [Related]
10. PKI-587 and sorafenib targeting PI3K/AKT/mTOR and Ras/Raf/MAPK pathways synergistically inhibit HCC cell proliferation.
Gedaly R; Angulo P; Hundley J; Daily MF; Chen C; Evers BM
J Surg Res; 2012 Aug; 176(2):542-8. PubMed ID: 22261591
[TBL] [Abstract][Full Text] [Related]
11. Tumor-specific low molecular weight forms of cyclin E induce genomic instability and resistance to p21, p27, and antiestrogens in breast cancer.
Akli S; Zheng PJ; Multani AS; Wingate HF; Pathak S; Zhang N; Tucker SL; Chang S; Keyomarsi K
Cancer Res; 2004 May; 64(9):3198-208. PubMed ID: 15126360
[TBL] [Abstract][Full Text] [Related]
12. cAMP-dependent cytosolic mislocalization of p27(kip)-cyclin D1 during quinol-thioether-induced tuberous sclerosis renal cell carcinoma.
Cohen JD; Tham KY; Mastrandrea NJ; Gallegos AC; Monks TJ; Lau SS
Toxicol Sci; 2011 Aug; 122(2):361-71. PubMed ID: 21693435
[TBL] [Abstract][Full Text] [Related]
13. Hbo1 is a cyclin E/CDK2 substrate that enriches breast cancer stem-like cells.
Duong MT; Akli S; Macalou S; Biernacka A; Debeb BG; Yi M; Hunt KK; Keyomarsi K
Cancer Res; 2013 Sep; 73(17):5556-68. PubMed ID: 23955388
[TBL] [Abstract][Full Text] [Related]
14. Synergistic activity of letrozole and sorafenib on breast cancer cells.
Bonelli MA; Fumarola C; Alfieri RR; La Monica S; Cavazzoni A; Galetti M; Gatti R; Belletti S; Harris AL; Fox SB; Evans DB; Dowsett M; Martin LA; Bottini A; Generali D; Petronini PG
Breast Cancer Res Treat; 2010 Nov; 124(1):79-88. PubMed ID: 20054642
[TBL] [Abstract][Full Text] [Related]
15. Sorafenib and rapamycin induce growth suppression in mouse models of hepatocellular carcinoma.
Huynh H; Ngo VC; Koong HN; Poon D; Choo SP; Thng CH; Chow P; Ong HS; Chung A; Soo KC
J Cell Mol Med; 2009 Aug; 13(8B):2673-2683. PubMed ID: 19220580
[TBL] [Abstract][Full Text] [Related]
16. PI-103 and sorafenib inhibit hepatocellular carcinoma cell proliferation by blocking Ras/Raf/MAPK and PI3K/AKT/mTOR pathways.
Gedaly R; Angulo P; Hundley J; Daily MF; Chen C; Koch A; Evers BM
Anticancer Res; 2010 Dec; 30(12):4951-8. PubMed ID: 21187475
[TBL] [Abstract][Full Text] [Related]
17. The tumor-specific hyperactive forms of cyclin E are resistant to inhibition by p21 and p27.
Wingate H; Zhang N; McGarhen MJ; Bedrosian I; Harper JW; Keyomarsi K
J Biol Chem; 2005 Apr; 280(15):15148-57. PubMed ID: 15708847
[TBL] [Abstract][Full Text] [Related]
18. Roscovitine confers tumor suppressive effect on therapy-resistant breast tumor cells.
Nair BC; Vallabhaneni S; Tekmal RR; Vadlamudi RK
Breast Cancer Res; 2011 Aug; 13(3):R80. PubMed ID: 21834972
[TBL] [Abstract][Full Text] [Related]
19. A novel interaction between HER2/neu and cyclin E in breast cancer.
Mittendorf EA; Liu Y; Tucker SL; McKenzie T; Qiao N; Akli S; Biernacka A; Liu Y; Meijer L; Keyomarsi K; Hunt KK
Oncogene; 2010 Jul; 29(27):3896-907. PubMed ID: 20453888
[TBL] [Abstract][Full Text] [Related]
20. The farnesyl transferase inhibitor lonafarnib inhibits mTOR signaling and enforces sorafenib-induced apoptosis in melanoma cells.
Niessner H; Beck D; Sinnberg T; Lasithiotakis K; Maczey E; Gogel J; Venturelli S; Berger A; Mauthe M; Toulany M; Flaherty K; Schaller M; Schadendorf D; Proikas-Cezanne T; Schittek B; Garbe C; Kulms D; Meier F
J Invest Dermatol; 2011 Feb; 131(2):468-79. PubMed ID: 20944654
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
